Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa + pomalidomide + dexamethasone
isatuximab-irfc + pomalidomide + dexamethasone · Sanofi-Aventis U.S.
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with multiple myeloma after at least two prior therapies, including lenalidomide and a proteasome inhibitor.
LAMPGEN ANALYSIS
Why it matters
Introduced an anti-CD38 antibody option with pomalidomide and dexamethasone.
What research teams should watch
Plan infusion monitoring and notify the blood bank before treatment because compatibility testing can be affected.
PRIMARY RECORDS